H1N1 viral proteome peptide microarray predicts individuals at risk for H1N1 infection and segregates infection versus Pandemrix® vaccination

Immunology

Volumn 145, Issue 3, 2015, Pages 357-366

  Ambati, Aditya ^a,b   Valentini, Davide ^a,b   Montomoli, Emanuele ^c   Lapini, Guilia ^d   Biuso, Fabrizio ^d   Wenschuh, Holger ^e   Magalhaes, Isabelle ^a,b   Maeurer, Markus ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF SIENA   (Italy)

^d VisMederi Srl   (Italy)

^e JPT Peptide Technologies GmbH   (Germany)

Author keywords

Epitopes; Haemagglutinin; Immunoglobulin G; Influenza; Peptide microarray; Vaccination

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; PROTEOME; EPITOPE; SIALIDASE; VIRUS HEMAGGLUTININ;

ADULT; ANTIBODY BLOOD LEVEL; ANTIGEN RECOGNITION; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOREACTIVITY; INFECTION RISK; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; MAJOR CLINICAL STUDY; MALE; NONHUMAN; NOSE SMEAR; PANDEMIC INFLUENZA; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN MICROARRAY; RECEPTOR BINDING; SEASONAL INFLUENZA; SWEDEN; AMINO ACID SEQUENCE; BLOOD; COHORT ANALYSIS; EPITOPE MAPPING; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA, HUMAN; METABOLISM; MOLECULAR GENETICS; PHYSIOLOGY; PROCEDURES; PROGNOSIS; PROTEOMICS; REPRODUCIBILITY; RISK FACTOR; VACCINATION; VIROLOGY;

AMINO ACID SEQUENCE; COHORT STUDIES; EPITOPE MAPPING; EPITOPES; HEMAGGLUTININS, VIRAL; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOGLOBULIN G; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MOLECULAR SEQUENCE DATA; NEURAMINIDASE; PROGNOSIS; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; VACCINATION;

EID: 84931578131     PISSN: 00192805     EISSN: 13652567     Source Type: Journal    
DOI: 10.1111/imm.12448     Document Type: Article

References (59)

1. Novel Swine-Origin Influenza AVIT, Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360:2605-15.
2. Garten RJ, Davis CT, Russell CA et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 2009; 325:197-201.
3. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009; 459:931-9.
4. Peiris JS, Tu WW, Yen HL. A novel H1N1 virus causes the first pandemic of the 21st century. Eur J Immunol 2009; 39:2946-54.
5. The 2009 A(H1N1) Pandemic in Europe. Stockholm: ECDC, 2010. URL http://www.ecdc.europa.eu/en/publications/Publications/101108_SPR_pandemic_experience.pdf [accessed on 3 February 2011]
6. Hancock K, Veguilla V, Lu X et al. Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus. N Engl J Med 2009; 361:1945-52.
7. Fisman DN, Savage R, Gubbay J, Achonu C, Akwar H, Farrell DJ, Crowcroft NS, Jackson P. Older age and a reduced likelihood of 2009 H1N1 virus infection. N Engl J Med 2009; 361:2000-1.
8. Itoh Y, Shinya K, Kiso M et al. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 2009; 460:1021-5.
9. Greenbaum JA, Kotturi MF, Kim Y et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci USA 2009; 106:20365-70.
10. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 1982; 31:417-27.
11. Skehel JJ, Wiley DC. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu Rev Biochem 2000; 69:531-69.
12. Krause JC, Tumpey TM, Huffman CJ et al. Naturally occurring human monoclonal antibodies neutralize both 1918 and 2009 pandemic influenza A (H1N1) viruses. J Virol 2010; 84:3127-30.
13. Gamblin SJ, Skehel JJ. Influenza hemagglutinin and neuraminidase membrane glycoproteins. J Biol Chem 2010; 285:28403-9.
14. Couch RB, Kasel JA. Immunity to influenza in man. Annu Rev Microbiol 1983; 37:529-49.
15. Gaseitsiwe S, Valentini D, Mahdavifar S et al. Pattern recognition in pulmonary tuberculosis defined by high content peptide microarray chip analysis representing 61 proteins from M. tuberculosis. PLoS ONE 2008; 3:e3840.
16. Perez-Bercoff L, Valentini D, Gaseitsiwe S et al. Whole CMV proteome pattern recognition analysis after HSCT identifies unique epitope targets associated with the CMV status. PLoS ONE 2014; 9:e89648.
17. Huang S, Preuss KD, Xie X, Regitz E, Pfreundschuh M. Analysis of the antibody repertoire of lymphoma patients. Cancer Immunol Immunother 2002; 51:655-62.
18. Di Modugno F, Bronzi G, Scanlan MJ et al. Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response. Int J Cancer 2004; 109:909-18.
19. Chen YT, Scanlan MJ, Sahin U et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94:1914-8.
20. Chen YT, Gure AO, Tsang S, Stockert E, Jager E, Knuth A, Old LJ. Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA 1998; 95:6919-23.
21. Karasavvas N, Billings E, Rao M et al. The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res Hum Retroviruses 2012; 28:1444-57.
22. Engvall E, Perlmann P. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry 1971; 8:871-4.
23. Davidson E, Doranz BJ. A high-throughput shotgun mutagenesis approach to mapping B-cell antibody epitopes. Immunology 2014; 143:13-20.
24. Sharon J, Rynkiewicz MJ, Lu Z, Yang CY. Discovery of protective B-cell epitopes for development of antimicrobial vaccines and antibody therapeutics. Immunology 2014; 142:1-23.
25. Almqvist C, Adami HO, Franks PW et al. LifeGene - a large prospective population-based study of global relevance. Eur J Epidemiol 2011; 26:67-77.
26. Maeurer M. Markus Maeurer on the LifeGene project. Expert Rev Clin Immunol 2010; 6:709-12.
27. Magalhaes I, Eriksson M, Linde C et al. Difference in immune response in vaccinated and unvaccinated Swedish individuals after the 2009 Influenza pandemic. BMC Infect Dis 2014; 14:319.
28. Nahtman T, Jernberg A, Mahdavifar S, Zerweck J, Schutkowski M, Maeurer M, Reilly M. Validation of peptide epitope microarray experiments and extraction of quality data. J Immunol Methods 2007; 328:1-13.
29. Ngo Y, Advani R, Valentini D, Gaseitsiwe S, Mahdavifar S, Maeurer M, Reilly M. Identification and testing of control peptides for antigen microarrays. J Immunol Methods 2009; 343:68-78.
30. Valentini D, Gaseitsiwe S, Maeurer M. Humoral 'reactome' profiles using peptide microarray chips. Trends Immunol 2010; 31:399-400.
31. Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE Jr, Wilson IA. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science 2010; 328:357-60.
32. DuBois RM, Aguilar-Yanez JM, Mendoza-Ochoa GI, Oropeza-Almazan Y, Schultz-Cherry S, Alvarez MM, White SW, Russell CJ. The receptor-binding domain of influenza virus hemagglutinin produced in Escherichia coli folds into its native, immunogenic structure. J Virol 2011; 85:865-72.
33. Jmol: an open-source Java viewer for chemical structures in 3D. URL http://www.jmol.org/ [accessed on 20 January 2014]
34. Rowe T, Abernathy RA, Hu-Primmer J et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999; 37:937-43.
35. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98:5116-21.
36. Gentleman RC, Carey VJ, Bates DM et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5:R80.
37. Chi C-Y, Liu C-C, Lin C-C, Wang H-C, Cheng Y-T, Chang C-M, Wang J-R. Preexisting antibody response against 2009 pandemic influenza H1N1 viruses in the Taiwanese population. Clin Vaccine Immunol 2010; 17:1958-62.
38. Liu X, Liu Y, Zhang Y et al. Pre-existing immunity with high neutralizing activity to 2009 pandemic H1N1 influenza virus in Shanghai population. PLoS ONE 2013; 8:e58810.
39. Pichyangkul S, Krasaesub S, Jongkaewwattana A et al. Pre-existing cross-reactive antibodies to avian influenza H5N1 and 2009 pandemic H1N1 in US military personnel. Am J Trop Med Hyg 2014; 90:149-52.
40. Xing Z, Cardona CJ. Preexisting immunity to pandemic (H1N1) 2009. Emerg Infect Dis 2009; 15:1847-9.
41. Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD. A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 2008; 181:4168-76.
42. Pinna D, Corti D, Jarrossay D, Sallusto F, Lanzavecchia A. Clonal dissection of the human memory B-cell repertoire following infection and vaccination. Eur J Immunol 2009; 39:1260-70.
43. LaMere MW, Lam H-T, Moquin A, Haynes L, Lund FE, Randall TD, Kaminski DA. Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol 2011; 186:4331-9.
44. Wahl A, Schafer F, Bardet W, Buchli R, Air GM, Hildebrand WH. HLA class I molecules consistently present internal influenza epitopes. Proc Natl Acad Sci USA 2009; 106:540-5.
45. Anderson RW, Bennink JR, Yewdell JW, Maloy WL, Coligan JE. Influenza basic polymerase 2 peptides are recognized by influenza nucleoprotein-specific cytotoxic T lymphocytes. Mol Immunol 1992; 29:1089-96.
46. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007; 357:1903-15.
47. LaMere MW, Moquin A, Lee FE-H et al. Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J Virol 2011; 85:5027-35.
48. Schulman JL, Kilbourne ED. Independent variation in nature of hemagglutinin and neuraminidase antigens of influenza virus: distinctiveness of hemagglutinin antigen of Hong Kong/68 virus. Proc Natl Acad Sci 1969; 63:326-33.
49. Murphy BR, Kasel JA, Chanock RM. Association of serum anti-neuraminidase antibody with resistance to influenza in man. N Engl J Med 1972; 286:1329-32.
50. Tsukamoto M, Hiroi S, Adachi K et al. Antibodies against swine influenza virus neutralize the pandemic influenza virus A/H1N1. Mol Med Rep 2011; 4:209-14.
51. Shope RE. The incidence of neutralizing antibodies for swine influenza virus in the sera of human beings of different ages. J Exp Med 1936; 63:669-84.
52. Khurana S, Loving CL, Manischewitz J, King LR, Gauger PC, Henningson J, Vincent AL, Golding H. Vaccine-induced anti-HA2 antibodies promote virus fusion and enhance influenza virus respiratory disease. Sci Transl Med 2013; 5:200ra114.
53. Wiley DC, Wilson IA, Skehel JJ. Structural identification of the antibody-binding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation. Nature 1981; 289:373-8.
54. Li Y, Myers JL, Bostick DL et al. Immune history shapes specificity of pandemic H1N1 influenza antibody responses. J Exp Med 2013; 210:1493-500.
55. Koel BF, Burke DF, Bestebroer TM et al. Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science 2013; 342:976-9.
56. Mozdzanowska K, Furchner M, Washko G, Mozdzanowski J, Gerhard W. A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro. J Virol 1997; 71:4347-55.
57. Feng JQ, Mozdzanowska K, Gerhard W. Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype. J Virol 2002; 76:1369-78.
58. Monsalvo AC, Batalle JP, Lopez MF et al. Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med 2011; 17:195-9.
59. To KKW, Zhang AJX, Hung IFN et al. High titer and avidity of nonneutralizing antibodies against influenza vaccine antigen are associated with severe influenza. Clin Vaccine Immunol 2012; 19:1012-8.